PHT Corporation and OmniComm Systems Inc. Sponsor Executive Briefing on Corporate Risk Management and Clinical Trials
Global ePRO and EDC market leaders offer crucial information regarding FDA guidelines and the use of technology in clinical trials
BOSTON, Mass – October 22, 2009 – PHT Corporation and OmniComm Systems, Inc. hosted a successful Executive Briefing last month for senior level pharmaceutical and biotechnology Executives. The meeting provided new information on the regulatory and financial implications of recent FDA actions and an overview of how EDC and ePRO technologies shorten clinical development timelines and improve trial safety.
OmniComm and PHT are committed to serving the clinical research industry with relevant regulatory information and technologies that serve science. PHT is the leading provider of ePRO solutions used in more than 400 clinical trials worldwide. OmniComm provides customer-driven eClinical solutions, used in over 2000 clinical trials worldwide, to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research.
The two-hour session, “Corporate Risk Management and Clinical Trials: How to Minimize Your Exposure,” instructed attendees on how to diminish the number of mid-trial changes and abate the collection of insubmissable data, and discussed recreating trial conditions for regulatory agencies.
Led by OmniComm and PHT, the meeting included presentations by a former-FDA consultant and a data management expert from a local biotechnology company.
About PHT Corporation
PHT is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in more than 400 clinical trials by 100 biopharmaceutical clients. The proven LogPad® System and revolutionary SitePad® Tablet deliver the voice of the patient, in 88 languages, from homes and sites in 65 countries around the world. By capturing high-quality and time-stamped assessments with minimal respondent burden, trial sponsors are able to run smaller and more conclusive clinical research programs resulting in significant R&D cost savings. Real-time study management through PHT StudyWorks™ features eClinical data integration, standard and custom data summaries for compliance and enrollment, SafetyPRO™ email alerts, and the industry’s premier study archive. Patient experiences captured firsthand by PHT’s ePRO Product Suite have been used successfully in at least 12 NDA submissions and seven approvals to date. For more information, review interactive product demonstrations at the award-winning www.phtcorp.com.
PHT, LogPad, eSense, StudyWorks, SafetyPRO and SitePad are among the registered trademarks and trademarks of PHT Corporation.
About OmniComm Systems, Inc.
Omnicomm Systems (www.omnicomm.com) provides customer-driven eClinical solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.
Media Contact: Brenda Nashawaty, bnashawaty@phtcorp.com, 617-688-3253
Catherine Lemercier, clemercier@omnicomm.com, 954-377-1728
###
